ASCO Guidelines on VTE Add New Oral Agents

Tony Berberabe, MPH @OncBiz_Wiz
Published: Tuesday, Nov 19, 2019
Gary H. Lyman, MD, MPH

Gary H. Lyman, MD, MPH
Updated venous thromboembolism (VTE) guidelines issued by the American Society of Clinical Oncology (ASCO) now include the use of direct oral anticoagulants (DOACs) for patients with cancer as a preventive measure against VTE recurrence.

It is common for unsuspected blood clots to be detected at the time of routine baseline staging imaging, such as during CT scans, said Lyman. “Those patients should be treated for their VTE with therapeutic doses of anticoagulation. Whether all patients without symptoms should be screened with baseline ultrasounds remains controversial and variable in practice. It would seem reasonable to offer baseline screening ultrasounds to high-risk patients based on their risk score. However, the limited benefit and increased cost probably do not justify routine screening to non–high–risk patients.”

Table 1. Six Questions and Recommendations About VTE Prevention and Treatment1 (Click to Enlarge)

Risk Model

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication